New ASN Kidney Translation Podcast episode reviews 2 late-breaking clinical trials published simultaneously with #KidneyWk: empagliflozin in ADPKD and upacicalcet for secondary hyperparathyroidism in hemodialysis. kidney.pub/KTPOD102426

Advancing kidney therapeutics and amplifying patient voices, Aliza Thompson, MD, MS, is the inaugural recipient of the joint ASN-NKF award. Her leadership at the FDA has helped move kidney disease drug development forward. #ASNKidneyNews
kidney.pub/KN1810-27

Advancing ADPKD Research!

Dr. Stephen Seliger presented collaborative research on empagliflozin therapy in ADPKD at ASN Kidney Week 2026. Congratulations to Drs. Seliger and Chonchol!

Publication: pubmed.ncbi.nlm.nih.gov/42925875/

#ADPKD #KidneyResearch

Our kidneys have their own “body clock.” A #basicresearch study in #ASNKidney360 suggests that in ADPKD, that clock may be disrupted as cysts grow. Researchers hope these findings could lead to new ways to protect kidney function in the future. kidney.pub/KID1347

New in #ASNJASN and simultaneously published with #KidneyWk: Study found empagliflozin 25 mg once daily for 12 months was safe & well-tolerated in adults with ADPKD at high risk for rapid progression. Those treated with empagliflozin had greater increase in kidney volume kidney.pub/JASN1271

Stronger together!!! Excellent day with The PKD RRC team at ASN kidney week. @American society of Nephrology @pkdresearch

University of Kansas nephrology
@KUNeph @KUJGKI are in Denver for @ASNKidney #KidneyWk

Basic Research published in #ASNJASN identified a protein called ARL13B that helps drive cyst growth in polycystic kidney disease. In mice, blocking this protein reduced cyst growth and improved kidney health, suggesting it could be a possible target for future treatments. kidney.pub/JASN1238

New research published in #ASNJASN helps explain why people with chronic kidney disease are more prone to blood clots and points to a potential new target for preventing these serious complications. kidney.pub/JASN1203

Could a novel CHAR T-cell therapy provide a targeted way to desensitize kidney transplant candidates with HLA-DQ antibodies? Read #BasicResearch #ASNJASN to find out. kidney.pub/JASN1244

Huge disappointment. High hopes...dashed

Some people with HIV who carry high-risk APOL1 genes may be less likely to develop kidney disease if they also have the APOL1 p.N264K genetic variant. This finding in #ASNJASN may help doctors better understand an individual's kidney disease risk in the future. kidney.pub/JASN1235

🏆 Lillian Jean Kaplan Prize for PKD: Feng Qian. Learn more: bit.ly/4xANJpj

“I am deeply honored and humbled to receive the Lillian Jean Kaplan International Prize. This recognition reflects the collective efforts of many outstanding colleagues, trainees, collaborators, ributions have advanced our understanding of polycystic kidney disease. While significant progress has been made, important challenges remain. I look forward to continuing the pursuit of discoveries that deepen our understanding of PKD and ultimately improve the lives of patients and families affected by this disease.” Prof. Qian

Measuring slit diaphragm autoantibodies could transform care by distinguishing low-risk from high-risk autoimmune podocytopathies, improving prognosis, treatment selection, and transplant planning, according to new study in #ASNJASN. kidney.pub/JASN1195

APOL1 risk variants (G1/G2) form membrane pores that increase Ca²⁺ influx and kidney cell damage. The APOL1 inhibitor VX-147 and the M1 (N264K) variant reduced Ca²⁺ entry and improved cell survival, highlighting potential therapies for APOL1 kidney disease. #ASNJASN kidney.pub/JASN1159?utm_s…

#BasicResearch study in #ASNJASN shows that blocking gut microbial TMAO production reversed key features of established CKD in mice, further implicating the gut-kidney axis as a promising therapeutic target. kidney.pub/JASN1171?utm_s…

Our new study in @JASN_News: Autoantibody specificity matters: anti-nephrin, anti-podocin, and anti-KIRREL1 antibodies define autoimmune podocytopathies with distinct phenotypes, prognosis, and transplant recurrence risk. ovid.com/jnls/jasn/abst…

@polymath1959 But @kidney_boy does! It’s all about a low urine output for a bit!

New ADPKD #basicresearch identifies the PTH–Pth1r–primary cilia pathway as a driver of kidney cyst growth. Blocking Pth1r reduced cyst progression in mouse models, while cinacalcet lowered PTH levels and cyst burden, highlighting a promising new therapeutic target. #ASNJASN kidney.pub/JASN1170?utm_s…